what are the Recommendation for the Management of Stage C HF: Ivabradine
Referenced studies that support the recommendation are summarized
in the Online Data Supplements.?
For patients with symptomatic (NYHA class II to III) stable chronic HFrEF (LVEF ?35%) who are receiving GDMT, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of ?70 bpm at rest, ivabradine can be beneficial to reduce HF hospitalizations and cardiovascular death.